 |
News Search |
 |
 |
 |
Neurogenesis Gets a Jolt From Enhanced APP Processing, Curcumin
|
 |
 |
|
 |
 |
4 April 2008. The birth of new neurons in the adult brain intimates a capacity for restoration even in the face of aging and neurodegeneration. Two papers published in the March 24 issue of the Journal of Biological Chemistry online highlight a pair of scenarios where neurogenesis could come into play in Alzheimer disease. One study, from Thomas Willnow and colleagues at the Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany, indicates that lack of the trafficking receptor SORLA causes overproduction of soluble APP products and increased neurogenesis. Both decreased SORLA and increased neurogenesis have been observed in AD brain, and the study provides a possible link between the two.
The second study, from Jaewon Lee and colleagues at Pusan National University in Korea, presents evidence that curcumin, a component of curry spice with anti-inflammatory, antioxidant and anti-amyloid activity, also enhances neurogenesis in the brain of adult mice. Though it is not clear if neurogenesis explains curcumin’s repertoire of actions, the results suggest another way in which the compound might benefit the brain.
In the SORLA story, previous work from Willnow and colleagues showed that SORLA, also an ApoE receptor and alternatively known as LR11, controls processing of the amyloid precursor protein (APP) by directing its travel through subcellular compartments (see ARF related news story). High levels of SORLA result in less APP cleavage, while the lower concentrations found in the brains of people with AD (Scherzer et al., 2004) or mild cognitive impairment (Sager et al., 2007) may promote amyloidogenic processing of APP. SORLA is particularly interesting because it is decreased in brains of people with sporadic AD, but not familial disease, suggesting the reduction may be a cause of pathology, not a result. Consistent with this idea, polymorphisms in the gene encoding SORLA (SORL1) have been associated with late-onset AD (see ARF related news story and AlzGene entry).
In the new study, authors Michael Rohe and Anne-Sophie Carlo used SORLA knockout mice (Andersen et al., 2005) to understand the physiological role of the protein and its effects on Aβ pathology in vivo. Their results coincide with previous studies in cells, suggesting that SORLA serves to keep the lid on amyloidogenic APP processing. SORLA knockout mice, they show, had lower levels of full-length APP and higher amounts of APP cleavage products in the hippocampus. When they crossed SORLA knockout mice with PDAPP mice expressing a mutated form of human APP, the offspring showed increases in the levels of soluble APP products and Aβ40 peptide in the hippocampus and a threefold in increase in plaque burden. These results suggest that the diminished SORLA levels seen in sporadic AD could encourage senile plaque formation. Nonetheless, the investigators did not see changes in synaptic transmission in the hippocampus of SORLA-lacking mice compared to the impairments already seen in the PDAPP parental mice.
Soluble APP fragments have been reported to stimulate MAP kinase pathways (Greenberg et al., 1994), which are important in neurogenesis. When the investigators looked in the SORLA-deficient mice, they found that the observed 50 percent increase in sAPP was accompanied by activation of the MAP kinase ERK. BrdU labeling to detect dividing cells revealed a threefold increase in the number of proliferating cells in the hippocampus shortly after labeling, and a twofold increase in the number of surviving BrdU-labeled cells four weeks later. This effect on neurogenesis was likely due to APP processing since labeled cells were not found in SORLA knockout mice that also lacked APP. The investigators conclude, “Our data document a role for SORLA not only in control of plaque burden, but also in APP-dependent neuronal signaling, and suggest a molecular explanation for increased neurogenesis observed in some AD patients.”
The second paper, a study of the effects of curcumin on neurogenesis, follows on two other reports of positive effects of the compound on neurogenesis in chronically stressed rats
(Xu et al., 2007) and in normal mice (Kang et al., 2006). Curcumin, a component of turmeric, the yellow spice that colors curries, has been shown to reduce plaque accumulation and improve cognitive function in mouse models, and inhibit Aβ aggregation (reviewed in Cole et al., 2007; see also ARF related news story and ARF news story). Based on these results, pilot clinical trials are in progress (see ARF related news story), and the results from one preliminary study in China were recently published (Baum et al., 2008).
The new work shows that curcumin at low concentrations increases the proliferation of neural progenitor cells in vitro, in association with its ability to activate the map kinases ERK and p38. In vivo, administration of curcumin to adult mice resulted in increased numbers of newly born cells both in the dentate gyrus of the hippocampus and in the subventricular region of the cerebral cortex of adult mice, centers of neurogenesis. Four weeks later, all the newborn cells had turned into neurons. The effect of curcumin on neurogenesis was similar to the impact of exercise and environmental enrichment. The stimulation of neurogenesis represents “another potential useful effect” of curcumin, says Greg Cole of the University of California at Los Angeles, who was not involved with this study but has worked on curcumin extensively. However, he said, “It is hard to know the significance yet.”—Pat McCaffrey.
References:
Rohe M, Carlo AS, Breyhan H, Sporbert A, Militz D, Schmidt V, Wozny C, Harmeier A, Erdmann B, Bales KR, Wolf S, Kempermann G, Paul SM, Schmitz D, Bayer TA, Willnow TE, Andersen OM. Sorla affects APP-dependent stimulation of erk signaling and adult neurogenesis. J Biol Chem. 2008 Mar 24; [Epub ahead of print] Abstract
Kim SJ, Son TG, Park HR, Park M, Kim MS, Kim HS, Chung HY, Mattson MP, Lee J.
Curcumin stimulates proliferation of embryonic neural progenitor cells and neurogenesis in the adult hippocampus. J Biol Chem. 2008 Mar 24; [Epub ahead of print] Abstract
|
 |
 |
 |
Comments on News and Primary Papers |
 |
 |
|
Comment by: Gregory Cole, ARF Advisor
|
 |
 |
Submitted 4 April 2008
|
Posted 4 April 2008
|
 |
 |
This new data on curcumin stimulated neurogenesis look pretty good and the dosing at 500nM to get the effect in vitro and via stimulation of MAPK is credible and consistent with other literature. Their in vivo results are the most important demonstration of possible utility. The dosing is higher than what people achieve with current supplements and the blood and brain levels represent estimates. They are at the high end, but the authors get the neurogenesis effect without toxicity, suggesting that it may be realizable within a therapeutic window.
One caveat for the relevance to AD for this and for most of the other studies showing stimulation of hippocampal neurogenesis is that the effects shown are usually in the dentate gyrus rather than in more AD vulnerable regions like CA1, entorhinal cortex and other areas showing neuron loss. That said, the increases in areas with normal neurogenesis, in the DG and in the cortical subventricular zone, suggests an effect might extend to other areas and might redistribute to areas of neuron loss in the presence of regional pathology.
View all comments by Gregory Cole
|
 |
|
|
Comment by: Tommaso Russo, ARF Advisor
|
 |
 |
Submitted 9 April 2008
|
Posted 9 April 2008
|
 |
 |
This interesting paper of Thomas Willnow and colleagues confirms that SORLA/LR11 has a significant role in the regulation of APP processing, thus giving further support to the hypothesis that reduced SORLA expression could be a risk factor for sporadic AD (Rogaeva et al., 2007).
In addition, the results suggest some other reflections. First, they confirm that, at least in mice, altered neuronal function and survival are not directly correlated with the amount of Aβ produced and with plaque burden. This is the umpteenth observation that draws our attention to this point, but we still don’t have a clear explanation for that. Second, the results contribute to the unsolved issue of APP functions. The observed molecular phenotypes are actually due to an increased processing of APP that leads to accumulation of secreted soluble APP. However, we should also take into account that increased processing of APP is also expected to affect AICD intracellular concentration. Thus, we cannot exclude that the observed phenotype could be due to altered AICD-dependent signaling. This...
Read more
View all comments by Tommaso Russo
|
 |
|
|
Primary Papers: Sortilin-related receptor with A-type repeats (SORLA) affects the amyloid precursor protein-dependent stimulation of ERK signaling and adult neurogenesis.
Comment by: George Perry (Disclosure)
|
 |
 |
Submitted 11 April 2008
|
Posted 11 April 2008
|
 |
 |
I recommend this paper
|
 |
 |
 |
Comments on Related Papers |
 |
 |
|
Related Paper: Curcumin: From ancient medicine to current clinical trials.
Comment by: Takaomi Saido, ARF Advisor
|
 |
 |
Submitted 15 March 2008
|
Posted 21 March 2008
|
 |
 |
I recommend this paper
|
 |
 |
 |
Comments on Related News |
 |
 |
|
Related News: Curry Ingredient Spices Things Up by Blocking Aβ Aggregation
Comment by: Erik Jansson
|
 |
 |
Submitted 26 December 2004
|
Posted 28 December 2004
|
 |
 |
I recommend the Primary Papers
Curcumin also impacts aluminum binding to chromatin DNA, which is of relevance. After aluminum mordanting of chicken blood smears, several chelating dyes and reagents were found to detect metal binding to chromatin DNA by fluorescence microscopy. One of them [the reagents] was curcumin. Aluminum is a risk factor for AD.
References: A.R. Llorente, P. Del Castillo, J.C. Stockert, Aluminum binding to chromatin DNA as revealed by formation of fluorescent complexes with 8-hydroxyquinoline and other ligands. J. Microsc 155 (Pt. 2) (1989) 227-30
View all comments by Erik Jansson
|
 |
|
|
Related News: Curry Ingredient Spices Things Up by Blocking Aβ Aggregation
Comment by: J. Lucy Boyd
|
 |
 |
Submitted 1 February 2005
|
Posted 1 February 2005
|
 |
 |
I recommend the Primary Papers
|
 |
|
|
Related News: SORLA Soars—Large Study Links Gene to Late-onset AD
Comment by: Rudy Tanzi (Disclosure)
|
 |
 |
Submitted 15 January 2007
|
Posted 15 January 2007
|
 |
 |
This new study showing association of SORL1 with late-onset Alzheimer disease (LOAD) provides further support for a role of this gene in AD, confirming earlier studies by Lah, Small, Gandy, Masters, and others implicating SORL1 in AD pathogenesis.
The novelty of this study is the inclusion of genetic association of several SNPs in SORL1 with various samples of different ethnicities. The results for specific SNPs across samples are interesting but inconsistent, with various SNPs showing positive results in some samples and negative data in others.
This is often the case for many novel AD candidate genes when tested in multiple samples, either in a single study or across multiple studies.
The Alzgene.org
database on Alzforum reveals no less than two dozen genes that exhibit statistically significant association with LOAD after meta-analyses of multiple samples. These can be found in the "Top Alzgene Results" box in the right margin of Alzgene. A full description of Alzgene and its findings can be found...
Read more
View all comments by Rudy Tanzi
|
 |
|
|
Related News: SORLA Soars—Large Study Links Gene to Late-onset AD
Comment by: John Hardy, ARF Advisor
|
 |
 |
Submitted 15 January 2007
|
Posted 15 January 2007
|
 |
 |
This work is welcome news from an excellent group of investigators. They will surely allow me to play devil’s advocate and caution two things. First, however enticing the cell biology might be, at this point it is a distraction. The question at hand is a genetic question, and to answer the genetics per se, the cell biology data is irrelevant. Unfortunately, journal editors often demand cell biology in genetics papers, even if it’s just an initial set of experiments.
Second, while many sample series were used, there is not an exact replication of the haplotypic association between the sample series, making these "replications," in my view, suspect. In this, the work resembles our own work (Li et al., 2006 and Grupe et al., 2006 on other risk genes). In these cases, too, we obtained multiple, but not entirely convincing replications.
Late-onset Alzheimer genetics is proving to be a very difficult problem. I personally doubt whether this is the new ApoE, but genuine attempts at...
Read more
View all comments by John Hardy
|
 |
|
|
Related News: SORLA Soars—Large Study Links Gene to Late-onset AD
Comment by: Rudy Tanzi (Disclosure)
|
 |
 |
Submitted 15 January 2007
|
Posted 15 January 2007
|
 |
 |
Update: With regard to my earlier comment on the SORL1-AD genetic association study by Rogaeva et al, I initially commented that on the Alzgene list of "Top Alzgene Results", SORL1 ranked 12th out of 25 genes. (Ranking is based on effects of SNPs in the gene on risk for AD, with APOE at number 1).
Lars Bertram has now revised that ranking on the most updated "Top Alzgene Results" list:
SORL1 ranks 18th out of 27 genes listed on "Top Alzgene Results" that have statistically significant effects on AD risk following meta-analyses.
View all comments by Rudy Tanzi
|
 |
|
|
Related News: Potential Therapies—Small Molecule Boosts for Immune Response, Neurogenesis
Comment by: Milan Fiala (Disclosure)
|
 |
 |
Submitted 6 August 2007
|
Posted 6 August 2007
|
 |
 |
Reply to Frautschy, Teter Comment
In response to the comments by Frautschy and others, the objectives of our paper are first to explain the immune mechanisms of amyloidosis in Alzheimer disease patients and second to find out what can be done about clearance of amyloidosis from the patient’s brain. The emerging answers are that amyloidosis is contributed by insufficient clearance by the Alzheimer patients’ innate immune system and that modulation of the innate immune system has positive effects on amyloid-β clearance.
There is no problem in distinguishing FITC-amyloid-β by fluorescence microscopy from curcuminoids, which (at 0.1 microM) are not visible by fluorescence microscopy. Amyloid-β is also revealed by immunostaining with amyloid-β antibody or by electron microscopy. This can be seen in the pictures of FITC-Aβ in Figs. 2, 3, 5 in the current PNAS publication (1) or the Figs. 2 and 3 (using anti-Aβ immunofluorescence or electron microscopy) in our previous publication (2). The responses of individual patients and...
Read more
View all comments by Milan Fiala
|
 |
 |
 |
| |
Submit a Comment on this News Article |
 |
 |
 |
 |
|